Stock AnalizModerna (MRNA) earnings for the quarter ended September 2026: EPS beats estimates
Moderna reported results for the quarter ended September 2026 on November 6, 2026. Adjusted earnings per share came in at $0.38 against the analysts’ average forecast of -$1.25, a beat of 130.3%.
Revenue for the quarter was $1.31 billion, up 29.2% from $1.02 billion in the same quarter a year earlier.
The market’s verdict: the stock rose 5.3% on the first trading day after the report.
The last four quarters
Moderna has beaten the analysts’ EPS forecast in 4 of the last 4 quarters.
| Quarter | EPS | Forecast | Surprise | Revenue growth | Price reaction |
|---|---|---|---|---|---|
| Sep 2026 | $0.38 | -$1.25 | +130.3% | +29% | +5.3% |
| Jun 2026 | -$1.97 | -$2.06 | +4.3% | +2% | −4.8% |
| Mar 2026 | -$3.40 | -$3.88 | +12.4% | +260% | +3.0% |
| Sep 2025 | -$0.51 | -$2.18 | +76.6% | −45% | +4.2% |
What comes next
Analysts expect EPS of -$2.14 for the next quarter on average and -$7.36 for the fiscal year ending December 31, 2026.
The average analyst price target is $158.47, 29% below the current price of $223.37.
Valuation and score
Moderna scores 1.0 out of 5 overall on Stock Analiz (weak). Full Moderna analysis with 10 years of financials
Frequently asked questions
What was Moderna’s EPS for the quarter ended September 2026?
$0.38 adjusted per share, against an analyst consensus of -$1.25.
How much revenue did Moderna report?
$1.31 billion, up 29.2% year over year.
More
This report was written automatically from the published numbers within hours of the release. It is information, not investment advice.